Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 May 2025 | Story Lilitha Dingwayo | Photo Lunga Luthuli
Mock Interview
UFS students shine with confidence at the 2025 Mock Interview Day, ready for career success.

To get senior and postgraduate students ready for the world of work, the University of the Free State (UFS) Division of Career Services’ Placement Preparation Day, which was initiated in 2023, has grown into an annual workshop – Mock Interview Day – with this year’s event taking place in the Callie Human Centre on the Bloemfontein Campus.   

Held on 14 and 15 May 2025, this UFS initiative – aimed at addressing employability – has evolved through the implementation of several educational subdivisions tasked with the responsibility of assisting all registered students understand the professional environment. One of these divisions is the Centre for Teaching and Learning’s (CTL) ‘Graduate Attributes’ – an initiative that seeks to assess a student’s development of valuable attributes during lectures.

According to Belinda Janeke, Assistant Director of Career Services, “Feedback indicates that most students have no interview experience – a critical factor. It is through these mock interviews that students’ confidence is built and their transition from student to employee is smoothened.” 

With the assistance of staff members and employees in conducting the interviews, the two-day initiative has seen evident success in both attendance and reach. “Yesterday we had about 90 students come in for the mock interviews and all of them stated that it was their first time being interviewed,” said Janeke. “Even though our office is situated on the Bloemfontein Campus, we also visit the South and Qwaqwa campuses to ensure accessibility across all three UFS campuses,” Janeke added. Emphasising results, she shared that in the 12 years she has been working in this division, student engagement has grown due to improvements in technology. 

Career Services sends out letters and emails on the 11th of each month to recognise the achievements of students who have used their services. In collaboration with the UFS’ Vision 130, more directions are being explored across the three campuses, starting with the cross-campus Shoe Camp project.

This initiative targets all UFS students, prioritising senior individuals on the cusp of job hunting. “As a postgraduate student, I am looking into getting a job next year and I have never been interviewed before, so I needed the trial run to get more information on accurate interview etiquette,” said Aphiwe Mbutuma, an Administration honours student. Mbutuma said the support she received from the staff was crucial in boosting her confidence for her next interview. She further described the experience as an eye-opener, adding that students should seize these opportunities to understand what is expected of them. Zukile Daki, a second-year student in the Faculty of Law, said: “I once bombed an interview, so I came here to improve, and it went well.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept